Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] plunged by -$6.37 during the normal trading session on Monday and reaching a high of $101.49 during the day while it closed the day at $98.48. The company report on November 29, 2022 that Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
THIS IS AN ANNOUNCEMENT OF A POSSIBLE OFFER UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”). IT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE IRISH TAKEOVER RULES AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, OR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE.
Horizon Therapeutics Public Limited Company stock has also gained 26.26% of its value over the past 7 days. However, HZNP stock has inclined by 65.15% in the 3 months of the year. Over the past six months meanwhile, it has gained 12.91% and lost -8.61% year-on date.
The market cap for HZNP stock reached $21.47 billion, with 230.33 million shares outstanding and 223.96 million shares in the current float. Compared to the average trading volume of 2.88M shares, HZNP reached a trading volume of 7069645 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Horizon Therapeutics Public Limited Company [HZNP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HZNP shares is $109.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HZNP stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Horizon Therapeutics Public Limited Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 01, 2022. The new note on the price target was released on August 04, 2022, representing the official price target for Horizon Therapeutics Public Limited Company stock. Previously, the target price had yet another raise to $139, while UBS analysts kept a Buy rating on HZNP stock.
The Average True Range (ATR) for Horizon Therapeutics Public Limited Company is set at 4.30, with the Price to Sales ratio for HZNP stock in the period of the last 12 months amounting to 5.80. The Price to Book ratio for the last quarter was 4.51, with the Price to Cash per share for the same quarter was set at 9.77. Price to Free Cash Flow for HZNP in the course of the last twelve months was 16.34 with Quick ratio for the last quarter at 3.70.
HZNP stock trade performance evaluation
Horizon Therapeutics Public Limited Company [HZNP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.26. With this latest performance, HZNP shares gained by 35.03% in over the last four-week period, additionally plugging by 12.91% over the last 6 months – not to mention a drop of -1.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HZNP stock in for the last two-week period is set at 74.47, with the RSI for the last a single of trading hit 74.41, and the three-weeks RSI is set at 72.86 for Horizon Therapeutics Public Limited Company [HZNP]. The present Moving Average for the last 50 days of trading for this stock 71.49, while it was recorded at 96.65 for the last single week of trading, and 82.75 for the last 200 days.
Horizon Therapeutics Public Limited Company [HZNP]: An insightful look at the core fundamentals
Horizon Therapeutics Public Limited Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 4.00.
Earnings per share (EPS) analysis for Horizon Therapeutics Public Limited Company [HZNP] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HZNP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Horizon Therapeutics Public Limited Company go to 12.00%.
Horizon Therapeutics Public Limited Company [HZNP]: Insider Ownership positions
There are presently around $20,733 million, or 97.00% of HZNP stock, in the hands of institutional investors. The top three institutional holders of HZNP stocks are: VANGUARD GROUP INC with ownership of 21,276,662, which is approximately 1.693% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 15,619,023 shares of the stock with an approximate value of $1.54 billion in HZNP stocks shares; and CAPITAL INTERNATIONAL INVESTORS, currently with $849.15 million in HZNP stock with ownership of nearly 12.488% of the company’s market capitalization.
Positions in Horizon Therapeutics Public Limited Company stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 259 institutional holders increased their position in Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] by around 42,218,616 shares. Additionally, 354 investors decreased positions by around 39,906,174 shares, while 66 investors held positions by with 128,403,359 shares. The mentioned changes placed institutional holdings at 210,528,149 shares, according to the latest SEC report filing. HZNP stock had 61 new institutional investments in for a total of 9,495,292 shares, while 136 institutional investors sold positions of 13,257,767 shares during the same period.